Island Pharmaceuticals is leveraging the WHO's MEURI framework alongside the FDA Animal Rule pathway to evaluate investigational antiviral, galidesivir, during Africa's Bundibugyo Ebola outbreak while advancing regulatory development for a potential broad-spectrum filovirus therapy.
